---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-003552"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:19:36.520740+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dermata raises ~$6.2M via warrant exercise at reduced price; issues new warrants

## Summary
- 4,834,470 existing warrants exercised at reduced price of $1.284/share, yielding $6.2M gross proceeds.
- New Series A warrants (5-year term) and Series B warrants (18-month term) issued, each exercisable at $1.284.
- New warrants require shareholder approval per Nasdaq Rule 5635(d); exercise limited to 4.99% (or 9.99%) ownership.
- H.C. Wainwright acted as exclusive financial advisor; fees include 7% cash plus 338,412 HCW warrants at $1.605.
- Company plans to use net proceeds for general corporate purposes including R&D and clinical trials.

## SEC filing metadata
- accession: 0001654954-25-003552
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495425003552/0001654954-25-003552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495425003552/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-003552
- JSON: https://secwatch.observer/filing/0001654954-25-003552.json
- Plain text: https://secwatch.observer/filing/0001654954-25-003552.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.